

# Management of asthma exacerbation in adults: guidelines for primary care doctors

Jerzy Kruszewski<sup>1</sup>, Ryszarda Chazan<sup>2</sup>, Krzysztof Kuziemski<sup>3</sup>, Barbara Rogala<sup>4</sup>,  
Wojciech Szczeklik<sup>5</sup>, Andrzej Dąbrowski<sup>6</sup>, Magdalena Twardowska<sup>7</sup>,  
Marzena Kościelna<sup>8,9</sup>, Elżbieta Kryj-Radziszewska<sup>10</sup>, Marek Oleszczyk<sup>10</sup>,  
Katarzyna Jankowska\*, Anna Bagińska<sup>9</sup>, Filip Mejza<sup>11</sup>

1 Clinic of Infectious Diseases and Allergology, Military Institute of Medicine, Warsaw, Poland

2 Department of Internal Medicine, Pneumology and Allergology, Medical University of Warsaw, Poland

3 Department of Pulmonology and Allergology, Department of Pulmonology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

4 Department of Internal Medicine, Allergology and Clinical Immunology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland

5 Department of Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Kraków, Poland

6 Department of Internal Medicine, Pneumology and Allergology, Medical University of Warsaw, Warsaw, Poland

7 Independent researcher, Kraków, Poland

8 Ewa Drohomirecka-Zach and Małgorzata Zawiaślan Primary Care Clinic, Kraków, Poland

9 Medycyna Praktyczna, Kraków, Poland

10 Department of Family Medicine, Chair of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland

11 Centre for Evidence Based Medicine, 2nd Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland

**Introduction** Asthma affects about 5% of the Polish adult population and despite modern treatments, exacerbations still affect a significant percentage of patients. In order to improve treatment efficacy of asthma exacerbations in Poland, we decided to adapt the established international guidelines on the management of asthma exacerbations to match the reality of the Polish healthcare system. The adaptation process was guided by the ADAPTE Collaboration toolkit.<sup>1</sup> The key stages included: determining health questions, searching for guidelines and other relevant documents followed by assessment of their quality, selecting the best guidelines and recommendations to create an adapted guideline.<sup>1,2</sup> Global Initiative for Asthma (GINA) Guidelines ([www.ginasthma.org](http://www.ginasthma.org)) were selected as the source document and relevant recommendations concerning asthma exacerbations were adopted and customized to match local conditions in Poland.<sup>3</sup> This document was endorsed by the Country Consultant in Family Medicine and College of Family Physicians in Poland. The current guidelines apply to adults with asthma.

The aim of the guidelines on the management of asthma exacerbations in adults is to improve the safety of patients by ensuring appropriate prevention of exacerbations and appropriate treatment.

**Target audience of the guidelines** The document is intended primarily for general practitioners (primary care physicians), general practice registrars, and general internal medicine registrars. However, the information provided in the guidelines may also be useful to healthcare managers and representatives of healthcare financing institutions and institutions responsible for the healthcare system structure.

**Implementation considerations** The current guidelines should not be seen as a legal standard of care for all patients. Instead, it provides some general management principles, which can aid clinical decision-making. Appropriate patient care options are always determined based on clinical situation and availability of treatments. All clinical decisions should always be consulted with the patient or their carer (if the patient lacks capacity).

**Strength of recommendations** The GINA Science Committee decided not to specify the strength of recommendations in their report, grading the quality of evidence supporting each recommendation instead. Similarly, the current guidelines provide the quality of evidence grade (see [TABLE 1](#)) supporting each recommendation only if the original document provided such information.<sup>3</sup> Otherwise, the Polish adaptation does not provide the quality of evidence grade.

## Correspondence to:

Anna Bagińska, Medycyna Praktyczna,  
Cholerzyn 445, 32-060 Liszki,  
Poland, phone: +48 12 293 40 00,  
email: [anna.baginska@mp.pl](mailto:anna.baginska@mp.pl)

Received: August 5, 2019.

Accepted: September 2, 2019.

Published online:

September 17, 2019.

Pol Arch Intern Med. 2019;

129 (11): 842-849

doi:10.20452/pamw.14978

Copyright by Medycyna Praktyczna,  
Kraków 2019

\* KJ is a representative of patients  
with asthma.

**TABLE 1** Description of evidence (quality) levels used in the reports of the Global Initiative for Asthma

Evidence level	Source(s) of evidence	Definition
A	RCTs and meta-analyses; rich body of data	Evidence is from endpoints of well-designed RCTs or meta-analyses that provide a consistent pattern of findings in the population for which the recommendation is made. Category A requires substantial numbers of studies involving substantial numbers of participants.
B	RCTs and meta-analyses; limited body of data	Evidence is from endpoints of intervention studies that include only a limited number of patients, post-hoc or subgroup analysis of RCTs or meta-analysis of such RCTs. Category B pertains when few randomized trials exist, they are small in size, they were undertaken in a population that differs from the target population of the recommendation, or the results are somewhat inconsistent.
C	Nonrandomized trials; observational studies	Evidence is from endpoints of uncontrolled or nonrandomized trials, or from observational studies.
D	Panel consensus judgement	This category is used only in cases where the provision of some guidance was deemed valuable but the clinical literature addressing the subject was insufficient to justify placement in one of the other categories. The panel consensus is based on clinical experience or knowledge that does not meet the above criteria.

Abbreviations: RCT, randomized clinical trial

### Definition and epidemiology of asthma exacerbations

Exacerbations of asthma are episodes characterized by worsening in symptoms (dyspnea, cough, wheeze, and chest tightness), which represent a change from the patient's usual status that is sufficient to require a change in treatment. The status asthmaticus (acute severe asthma, J46 according to the *International Classification of Diseases, Tenth Revision*) is defined as an episode of severe, life-threatening exacerbation of asthma.

The epidemiologic data is limited. In 2010, an estimated 8.2% of adults from the United States had current asthma, and approximately 50% of those had had an asthma attack in the past year.<sup>4</sup>

**Risk factors for asthma exacerbations** The key aspect in preventing asthma exacerbations is the awareness of risk factors, which include<sup>5-9</sup>:

- 1 Uncontrolled asthma symptoms (the key risk factor)
- 2 High use of short-acting  $\beta_2$ -agonist (SABA), which indicates uncontrolled asthma symptoms; mortality increased if one 200-dose canister is used per month
- 3 Inadequate use of inhaled corticosteroids (ICSs), nonadherence, poor inhaler technique
- 4 Low forced expiratory volume in 1 second (FEV<sub>1</sub>), especially if less than 60% predicted
- 5 Excessive (>10%) variability of peak expiratory flow (PEF); daily diurnal PEF variability should be calculated using the following formula: [PEFmax – PEFmin] / PEFmean; and averaged over 1 week.
- 6 Major psychological or socioeconomic problems
- 7 Exposures: smoking, allergen exposure if sensitized
- 8 Comorbidities: obesity, rhinosinusitis, confirmed food allergy
- 9 Sputum or blood eosinophilia, elevated fractional exhaled nitric oxide (in adults on long-term ICS)

10 Pregnancy

11 Ever intubated or in intensive care unit for asthma

12 One or more severe exacerbation in last 12 months

Items 1 to 9 are considered modifiable risk factors.

### Clinical presentation: diagnosing exacerbations

Asthma exacerbation manifests as an increased severity of dyspnea, cough, wheeze, and chest tightness that exceeds usual day-to-day variability.<sup>10</sup> The symptoms are usually accompanied by a decline in lung function (decreased PEF or FEV<sub>1</sub>) compared with the patient's previous lung function or predicted values (or maximum values for that patient). Lung function measurements enable objective assessment of exacerbation severity. Some patients (more often men or those with near-fatal asthma) may perceive symptoms poorly. The asthma control test is not a reliable tool to make a diagnosis of exacerbation.

Exacerbations usually occur in response to: exposure to an external agent (eg, viral upper respiratory tract infection, pollen, or pollution) and/or poor adherence with controller medication.<sup>11</sup> Some patients present more acutely and without exposure to known risk factors. Severe exacerbation can occur in patients with mild or well-controlled asthma.

**History and physical examination** The history taken from a patient with asthma exacerbation (or their next of kin in patients with severe exacerbation) should ascertain the following:

- Duration of exacerbation
- Potential causes if known (eg, allergen exposure or viral respiratory tract infection)
- Severity of asthma symptoms
- Presence and severity of other symptoms, in particular anaphylaxis

**TABLE 2** Factors that increase the risk of exacerbations and asthma-related death

- History of asthma exacerbation requiring intubation and mechanical ventilation
- Hospitalization or emergency care (emergency department) visit for asthma exacerbation in the past year
- Current or recent use of oral CS
- Not currently using ICS
- Overuse of SABA (using  $>1 \times 200$ -dose canister/mo is a red flag)
- History of psychiatric disease and/or psychosocial problems
- Poor adherence to asthma medications or poor adherence to (or lack of) a written asthma action plan
- Symptoms of food allergy

Abbreviations: CS, corticosteroid; ICS, inhaled corticosteroid; SABA, short-acting  $\beta_2$ -agonist

**TABLE 3** Asthma exacerbation severity assessment criteria according to the Global Initiative for Asthma 2018<sup>3</sup>

Parameter	Exacerbation severity		
	Mild/moderate	Severe	Life-threatening
Dyspnea/body position	Sits upright	Sits hunched forwards	Sits hunched forwards
Speech	Talks in phrases	Talks in words	Talks in words
Level of consciousness	Normal	Agitated	Drowsy, confused
Respiratory rate	Increased but $\leq 30$ breaths/min	$> 30$ breaths/min	$> 30$ breaths/min
Accessory muscles in use	No	Yes	Paradoxical breathing
Heart rate	100–120 bpm	$> 120$ bpm	$> 120$ bpm or bradycardia
PEF, % predicted	$> 50\%$	$\leq 50\%$	optionally
SpO <sub>2</sub> (on air)	90%–95%	$< 90\%$	$< 90\%$

Abbreviations: PEF, peak expiratory flow; SpO<sub>2</sub>, peripheral capillary oxygen saturation

• Risk factors for exacerbations and asthma-related death (see [TABLE 2](#))

• All current medications, including doses and devices prescribed, adherence pattern, any recent dose changes and response to current therapy

The physical examination of a patient with asthma exacerbation should assess<sup>12,13</sup>:

• Vital signs: level of consciousness, temperature, heart rate, respiratory rate, blood pressure

• Signs of bronchoconstriction (prolonged expiration, wheezing, rhonchi) and other abnormal findings of chest assessment (suggesting alternative conditions which may explain worsened patient's status, eg, pneumonia, pneumothorax, or heart failure)

• Additional findings, which facilitate objective assessment of exacerbation severity, such as ability to complete sentences or utter words, which may be impaired due to dyspnea, and use of accessory muscles

• Nonrespiratory signs suggesting alternative explanations of acute breathlessness (eg, stridor, rash, lower extremity edema)

The sensitivity of assessment based only on history and physical examination is limited, as symptom severity may not always accurately reflect the degree of bronchoconstriction in some patients.

**Additional investigations** The following tests should be performed in a patient with asthma exacerbation in a primary care setting.

#### Peak expiratory flow measurement or spirometry

Lung function tests (PEF and spirometry) are intended for the assessment of exacerbation severity and treatment efficacy.<sup>14</sup> They facilitate the decision to send patient home (eg, with PEF  $> 60\%$ – $80\%$  of predicted or personal best). In patients with asthma exacerbation, current PEF or FEV<sub>1</sub> values should be compared with previous measurements (if available) and with predicted or personal best values.

Lung function tests enable more objective, reliable assessment of exacerbation severity than clinical presentation.

Comment: Lung function tests should not be performed in patients who present with signs of severe exacerbation (see [TABLE 3](#)). PEF measurement can be preferred as easier and less demanding of a patient, except for the mildest cases, in which accurate lung function assessment may affect subsequent management.

**Pulse oximetry** Pulse oximetry facilitates assessing exacerbation severity.<sup>15</sup> Saturation levels (SpO<sub>2</sub>) of less than 90% signal the need for aggressive therapy. Pulse oximetry is useful for titrating oxygen therapy (target SpO<sub>2</sub> is 93%–95%) as well as for reviewing the response and the possibility to send the patient home (whereby SpO<sub>2</sub> of  $> 94\%$  when on air is required).

**Assessing the severity of exacerbation** Assessment of exacerbation severity should be based

on the degree of dyspnea, respiratory rate, heart rate, SpO<sub>2</sub>, and PEF (or FEV<sub>1</sub>). See TABLE 3.

**Criteria for hospitalization** The decision about hospitalization should be based on:

- Clinical status
- Lung function
- Response to treatment
- Recent and past history of exacerbations
- Ability to manage at home

Patients with severe or life-threatening exacerbation should be immediately transferred to the hospital. Whilst awaiting the transfer, the treatment outlined below should be initiated.

Comment: The decision to admit or discharge should be based on the clinical status (including the ability to lie flat) and lung function 1 hour after commencement of treatment rather than the patient's status on arrival.

The risk factors mentioned below should be considered to inform the decision to admit or discharge<sup>16</sup>:

- Female sex, older age, and nonwhite race
- Use of more than eight SABA puffs in the previous 24 hours
- Cardiopulmonary resuscitation or other emergency medical intervention at the emergency department
- Severe exacerbation (respiratory rate >30 breaths/min, oxygen saturation <90%, final PEF <50% predicted)
- Past history of severe exacerbations (eg, intubation)
- Previous unscheduled office and emergency department visits requiring use of oral CS.

Patients who are at risk of severe exacerbation and asthma-related death require prompt medical intervention and close monitoring (see TABLE 2).

**Management of asthma exacerbation** **Management of mild/moderate asthma exacerbation** Patients with mild/moderate asthma exacerbation can be managed by a general practitioner in a primary care setting. They should remain in the primary care facility for at least 1 hour after initial treatment. If there is an improvement in vital signs and PEF (>60%–80% of predicted or personal best), the patient does not need SABA, and has SpO<sub>2</sub> >94% when on air, they can be sent home after arranging follow-up visits.

Comment: Maintenance controller treatment with ICS at the dose 2- to 4-fold higher than the usual dose should be continued for 10 to 14 days.<sup>17</sup> With OCS, the maintenance treatment should be continued for 5 to 7 days.

**Short-acting  $\beta_2$ -agonist** Treatment of asthma exacerbation should start with SABA. It can be delivered by a pressurized metered-dose inhaler (pMDI) with a spacer or by a nebulizer.<sup>18,19</sup> The efficacy of both is comparable in patients with mild/moderate exacerbation (level of evidence, A). No additional SABA is needed if there is a good (PEF >60%–80% of predicted

or personal best), long-lasting (3–4 hours) response to initial treatment.

Dosage with pMDI with a spacer should be 4 to 10 puffs repeated every 20 minutes for 1 hour. After the first hour, depending on the response, the dose of SABA required varies from 4 to 10 puffs every 3 to 4 hours up to 6 to 10 puffs every 1 to 2 hours (or more often if needed). No additional SABA is needed if there is a good response to initial treatment (eg, PEF >60%–80% of predicted or personal best for 3–4 hours).

Dosage with nebulizer should be 2.5 to 5 mg of salbutamol, with the dose depending on the severity of exacerbation. A single dose of 2.5 to 5 mg administered over 30 minutes is usually sufficient. If needed, it can be repeated up to 4 times a day. Higher doses, up to 40 mg, can only be used in an inpatient setting.

Drugs available in Poland are: fenoterol (pMDI 100  $\mu$ g per puff), salbutamol (pMDI and DPI 100  $\mu$ g per puff and 200  $\mu$ g per puff, nebulizer solution 2.5 g/2.5 ml and 5 mg/2.5 ml, respectively).

**Oxygen therapy** Oxygen therapy should be used, if available, and titrated to maintain SpO<sub>2</sub> at 93% to 95%.<sup>20,21</sup> Such modality gives better clinical outcomes and is safer than high-flow 100% oxygen therapy (level of evidence, B). The unavailability of pulse oximeter is not a contraindication for oxygen therapy.

**Oral corticosteroids** Oral corticosteroids (OCSs) should be used in all patients, except for those with mildest exacerbations, especially if they fail to respond to an increase in reliever and controller medications after 2 to 3 days, deteriorate rapidly, have PEF or FEV<sub>1</sub> of less than 60% of their personal best or predicted value, or have a history of sudden severe exacerbations.

Prompt administration of systemic corticosteroids (oral or intravenous) improves clinical outcomes in patients with asthma exacerbation.<sup>22</sup> Systemic corticosteroids should be administered within 1 hour of presentation,<sup>23</sup> followed by a 5- to 7-day course with once a day (a.m.) administration (level of evidence, B). Oral administration is as effective as intravenous. Systemic corticosteroids enhance resolution of exacerbations and prevent relapse.

Dosage of prednisolone should be 1 mg/kg/d (maximum dose is 50 mg/d) or an equivalent dose of another OCS.

Drugs that are available in Poland are as follows: prednisone (tablets 1, 5, 10, and 20 mg), prednisolone (tablets 5 mg), methylprednisolone (tablets 4, 8, and 16 mg), triamcinolone (tablets 4 mg).

**Management of severe asthma exacerbation** Patients presenting with life-threatening asthma exacerbation/impaired consciousness should be transferred to the emergency department by the Advanced Life Support ambulance (the “S” category ambulance in Poland). In the remaining cases,



the Basic Life Support ambulance (the “P” category ambulance in Poland) is appropriate.

**Short-acting bronchodilator** Short-acting bronchodilators are best administered via an oxygen-powered nebulizer. If a nebulizer is not available, a pMDI with a spacer is the preferred delivery method.

Dosage of SABA should be 2.5 to 5 mg of salbutamol via a nebulizer (consider continuous nebulization at 10 mg/h or up to 10 doses administered every 20 minutes via a pMDI + spacer).

Dosage of short-acting muscarinic antagonist should be 0.5 to 0.75 mg of ipratropium bromide via a nebulizer or up to 10 doses administered via a pMDI with a spacer.

Ipratropium (pMDI 20 µg per puff, nebulizer solution 0.25 mg/ml) is available in Poland.

**Oxygen therapy** Oxygen therapy should be titrated to maintain SpO<sub>2</sub> at 93% to 95%.<sup>21</sup>

**Systemic corticosteroids** Systemic corticosteroids, oral or intravenous (comparable efficacy), should be administered within the first hour of treatment, dosage as in mild/moderate exacerbation.<sup>23</sup>

**Management of exacerbations in patients with asthma-chronic obstructive pulmonary disease overlap** The treatment should be in line with the guidance for the management of asthma and chronic obstructive pulmonary disease, including systemic corticosteroids administered shortly after presentation, stepped up inhaled bronchodilators (both SABA and short-acting muscarinic antagonist should be used; dosage, as above), controlled oxygen therapy, and antibiotics (if indicated).

**Adverse effects of drugs used for the management of asthma exacerbations** Although drugs used for the management of asthma hardly give systemic adverse effects, the risk of adverse effects increases with higher doses of medications administered to patients with exacerbations.

Comment: Hypoxemia, which may occur in patients with asthma exacerbation, may increase the risk of adverse effects of  $\beta_2$ -agonists. The most common adverse effects of  $\beta_2$ -agonists include: tachycardia and less often other arrhythmias (ectopic beats, atrial fibrillation); skeletal muscle tremor; hypokalemia; hyperglycemia.

Their presence and severity depend on the dose of a medication and the degree of hypoxemia. Therefore, high doses of  $\beta_2$ -agonists necessary to produce optimum bronchodilation should be used alongside oxygen therapy and corticosteroids, which can reduce the risk of adverse effects. The need to administer corticosteroids is likely to be overlooked due to the short-term bronchodilation effect of  $\beta_2$ -agonists, which may mask the severity of exacerbation.

**Medications not to be routinely used in the management of asthma exacerbation** Medications that

should not be routinely used in the management of asthma exacerbation include:

- Theophylline (due to low efficacy and high risk of adverse effects)<sup>25</sup>
- Antibiotics (unless there is a bacterial lower respiratory tract infection or pneumonia)
- Sedatives (contraindicated in asthma exacerbation)
- Adrenaline (except for patients whose bronchoconstriction is secondary to anaphylaxis)

**Assessing treatment response in patients with asthma exacerbation** The following should be monitored in patients with asthma exacerbation as a part of treatment response assessment: level of consciousness, respiratory rate, heart rate, SpO<sub>2</sub>, severity of dyspnea and other signs of exacerbation.

The patients should be periodically followed-up for the presence and severity of signs of exacerbation and changes in lung function (PEF measurement 1 hour after treatment commencement or earlier).

Patients with little or slow response to SABA treatment should be closely monitored.

Additional treatment should continue until PEF reaches a plateau or (ideally) returns to the patient's previous best.

Patients who fail to respond to treatment or who continue to deteriorate should be transferred immediately to an acute care facility.

**Follow-up after asthma exacerbation** In patients in whom a good control of exacerbation was achieved in a primary-care setting, a follow-up appointment should be arranged about 2 to 7 days later (level of evidence, D).

Once symptom control has been achieved, adherence should be assessed, and maintenance treatment planned.<sup>26</sup> Maintenance treatment should include initiation or stepping up the controller for 2 to 4 weeks or 2 to 3 months, depending on the cause of exacerbation). Most patients not currently taking controller medication should usually be commenced on regular ICS-containing therapy, as an exacerbation requiring medical care indicates that the patient is at increased risk of future exacerbations (level of evidence, B).

**Individualized asthma action plan** All patients should be provided with a written, individualized asthma action plan that includes current therapies and is appropriate for the patient's education and understanding.<sup>27</sup> The asthma action plan enables the patient to self-manage and respond appropriately to worsening symptoms of exacerbation and/or changes in PEF, providing guidance as to changes in reliever and controller medications, how to use OCSs, and when and how to access medical care (general practice / ambulance).<sup>28</sup>

After a self-managed exacerbation, patients should see their primary care healthcare provider within 1 to 2 weeks to assess symptom control and additional risk factors for exacerbations, and

**TABLE 4** Treatment modifications in adults with worsening asthma to be used in a written asthma action plan

Medications	Short-term change (1–2 weeks) for worsening asthma	Level of evidence
Increase usual reliever		
SABA	For pMDI, add spacer	A
Low-dose ICS/formoterol	Increase formoterol as needed up to the maximum of 72 µg/d	A
Usual controller, step-up treatment		
Maintenance and reliever ICS/formoterol	Continue maintenance ICS/formoterol and increase ICS/formoterol reliever (maximum formoterol total 72 µg/d)	A
Maintenance ICS + SABA as reliever	At least double ICS, consider increasing ICS to high dose (to maximum total of 2000 µg/d BDP equivalent)	B
Maintenance ICS/formoterol + SABA as reliever	Quadruple maintenance ICS/formoterol (maximum formoterol 72 µg/d)	B
Maintenance ICS/other LABA + SABA as reliever	Step up to higher dose formulation of ICS/other LABA or consider adding a separate ICS inhaler (to maximum total of 2000 µg/d BDP equivalent)	D
OCS (prednisone or prednisolone)	Add OCS in severe exacerbations (PEF or FEV <sub>1</sub> <60% personal best or predicted) or patient not responding to treatment over 48 hours	A
	Prednisolone 1 mg/kg/d (maximum 50 mg), usually for 5–7 d	D
	Tapering is not needed if a short-term (<2 weeks) OCS course is prescribed	B

Abbreviations: BDP, beclometasone dipropionate; FEV<sub>1</sub>, forced expiratory volume in 1 second; LABA, long-acting  $\beta_2$ -agonist; OCS, oral corticosteroid; PEF, peak expiratory flow; pMDI, pressurized metered-dose inhaler; others, see [TABLE 2](#)

to identify the potential cause of the exacerbation. Patients should contact their doctor if they start taking OCS.

During the follow-up appointment after a self-managed exacerbation, the written asthma action plan should be reviewed to see whether an update is needed.

Possible options for treatment modification as a part of self-management of asthma exacerbations are presented in [TABLE 4](#).

#### Treatment modifications as part of self-management of exacerbations

**Short-acting  $\beta_2$ -agonist** Repeated dosing with inhaled SABA bronchodilators provides temporary relief until the cause of the symptom worsening passes or treatment with an increased-dose controller has had time to take effect. SABA should be delivered via pMDI with a spacer or via a nebulizer. The need for repeated doses over more than 1 to 2 days signals the need to review, and possibly increase, controller treatment.

**Rapid-onset long-acting  $\beta_2$ -agonists (formoterol)** The use of the rapid-onset long-acting  $\beta_2$ -agonist, formoterol, in a separate inhaler is not recommended in order to avoid the possibility of it being used without the concomitant ICS.

**Inhaled corticosteroids** At least doubling the ICS dose as a part of asthma action plan–based self-management of exacerbation improves asthma outcomes and reduces healthcare utilization. Quadrupling the ICS dose (to an average of 2000 µg/d beclometasone dipropionate equivalent) in response to a decrease in PEF limits the need for OCS.<sup>29</sup>

In patients with an acute deterioration, high-dose ICS for 7 to 14 days (500–1600 µg beclometasone dipropionate equivalent) is as effective as a short course of OCS (level of evidence, A).

#### Combination inhaled corticosteroids with long-acting $\beta_2$ -agonist

The combination of rapid-onset long-acting  $\beta_2$ -agonist (formoterol) and low-dose ICS (budesonide or beclomethasone) in a single inhaler as both the controller and the reliever medication is effective in improving asthma control and reduces exacerbations requiring OCS and hospitalizations. The maximum total formoterol dose is 72 µg/d.<sup>30</sup>

The ICS dose may be further increased by adding a separate ICS inhaler.

**Patient education** Patients after exacerbations are more likely to implement behavioral changes. They should be referred to an asthma education program, if one is available.<sup>31</sup> It is particularly true for patients discharged following an emergency department presentation or hospitalization for asthma. Patients who were hospitalized may be particularly receptive to information and advice about their illness.

An educational program should contain in particular:

- Training aiming at effective use of inhaler devices (up to 70%–80% of patients are unable to use their inhaler correctly—poor inhaler technique leads to poor asthma control)
- Encouraging adherence (up to 50% of patients fail to take medications as directed at least part of the time)

**TABLE 5** Treating modifiable risk factors to reduce exacerbations

Patient group / risk factor	Treatment strategy	Level of evidence <sup>a</sup>
Any patient with $\geq 1$ risk factor for exacerbations (including poor symptom control)	Regular use of ICS	A
	A written action plan for the management of asthma	A
	More frequent reviews	A
	Regular control of inhaler technique	A
	Identification of modifiable risk factors	D
$\geq 1$ severe exacerbation in last year	Consider alternative controller regimens to reduce exacerbation risk, eg, ICS/formoterol maintenance and reliever regimen	A
	Consider stepping up treatment if no modifiable risk factors	A
	Identify any avoidable triggers for exacerbations	C
Exposure to tobacco smoke	Encourage smoking cessation	A
	Consider higher dose of ICS if asthma poorly-controlled	B
Low FEV <sub>1</sub> , especially if <60% predicted	Consider trial of 3-month treatment with high-dose ICS or 2-week treatment with OCS	B
	Exclude other lung disease, eg, COPD	D
	Refer for expert advice if no improvement	D
Obesity	Suggest weight loss	B
	Distinguish asthma symptoms from symptoms due to restrictive lung diseases and/or obstructive sleep apnea	D
Major psychological problems	Consider mental health assessment	D
	Help patient to distinguish between symptoms of anxiety and asthma; educate the patient how to manage panic attacks	D
Major socioeconomic problems	Offer less expensive medications	D
Confirmed food allergy	Advise appropriate food avoidance and remind the patient to have injectable epinephrine on them at all times <sup>b</sup>	A
Allergen exposure if sensitized	Consider possibility of reducing allergen exposure (consider cost)	C
	Consider stepping up of controller treatment	D
	Consider adding allergy immunotherapy, which is effective, but is associated with a risk of serious systemic adverse effects when administered subcutaneously	A
Sputum eosinophilia	Increase ICS dose independent of level of symptom control	A

**a** Level of evidence in the table applies to the efficacy of a given treatment in the management of asthma (assessed by means of different endpoints) rather than risk reduction in patients after exacerbations.

**b** Comment: The patient and their next of kin should be provided with detailed, preferably written, instructions for how and when to use the prescribed medications.

Abbreviations: COPD, chronic obstructive pulmonary disease; others, see TABLES 2 and 4

It should also include information regarding:

- Asthma
- The causes of asthma exacerbations and the ways to prevent them
- The actions the patient needs to take to respond to symptom worsening or a subsequent exacerbation

The strategies to reduce the risk of exacerbations are shown in TABLE 5.

**Review and update plan** The current document will be reviewed and updated as new important research data and the updated version of the GINA global strategy containing significant changes to the recommendations regarding management of asthma exacerbations become available.

#### ARTICLE INFORMATION

**ACKNOWLEDGMENTS** The current document was developed as a part of the POWR.05.04.00-00-0088/16-00 project "Upgrading skills and

qualifications of physicians through nationwide, standardized training in diagnostic management, treatment and prevention of diseases" (in Polish: Podnoszenie kwalifikacji lekarzy poprzez przeprowadzenie ogólnopolskich standaryzowanych szkoleń w zakresie postępowania diagnostycznego, terapii oraz profilaktyki), cofinanced from the European Union funds: the European Social Fund, priority axis 5—"Support for healthcare," activity 5.4 "Developing professional competences and qualifications of medical staff," the Operational Programme Knowledge Education Development. The financing institution has not influenced the content of the current guidelines.

**CONFLICT OF INTEREST** RC received a remuneration as a member of the advisory board from Berlin Chemie, Glaxo, Novartis, Adamed, Chiesi, and Lekam. AD received a conference grant from Venomenhal for EAACI congress. MK is the Chair of the Editorial Board of the *Lekarz Rodzinny* (General Practitioner) bi-monthly published by Medycyna Praktyczna and a co-organizer of the Medycyna Rodzinna – Nowości i Praktyka (General Practice – News and Practice) conference. Most activities are financed by the Medycyna Praktyczna publishing company as well as medical and pharmaceutical industry. JK received remunerations as a speaker from the medical and pharmaceutical industry. EK-R received a remuneration as a speaker during the GP training from Pierre Fabre Medicament Polska and is a partner in Praktyka Grupowa Lekarzy Rodzinnych Sp. z o.o. (GP Group Practice Ltd.) independent healthcare facility which has been commissioned healthcare services from the National Health Fund. KK received educational grants from Behringer Ingelheim and Bering to participate in the European Respiratory Society International Congress and the European Academy of Allergy and Clinical Immunology congress, EAACI 2017, as well as remunerations as a speaker from Behringer Ingelheim, ViaMedica, Agora Konferencje, KIMZE, Termedia, Medycyna Praktyczna, MediaMedical, Pharma2Pharma, Polpharma, and GSK. MO

participated in a clinical trial sponsored by Novartis and received remunerations as a speaker giving lectures on the management of asthma and chronic obstructive pulmonary disease from Astra Zeneca. As the Chair of the Masovian Branch of the Polish Society of Allergology, he organizes research and training conferences for the Branch, subsidized (venue and catering costs) by the pharmaceutical companies. BR received conference grants from CSL Behring and Chiesi for EAACI and AAAACI congresses. FM receives remunerations as a speaker from Sandoz, Chiesi, and Medycyna Praktyczna. AB, MT, KJ, and WS do not report any conflict of interest.

**OPEN ACCESS** This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.

**HOW TO CITE** Kruszewski J, Chazan R, Kuziński K, et al. Management of asthma exacerbation in adults: guidelines for primary care doctors. *Pol Arch Intern Med.* 2019; 129: 842-849. doi:10.20452/pamw.14978

## REFERENCES

- 1 The ADAPTE Collaboration. The ADAPTE process: resource toolkit for guideline adaptation. <http://www.g-i-n.net>. Published 2010. Accessed June 28, 2018.
- 2 Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. *CMAJ.* 2010; 182: E839-E842.
- 3 Global Initiative for Asthma. Global strategy for asthma management and prevention. <https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/>. Published 2018. Accessed June 28, 2018.
- 4 Mazurek JM, Syamlal G. Prevalence of asthma, asthma attacks, and emergency department visits for asthma among working adults - National Health Interview Survey, 2011-2016. *MMWR Morb Mortal Wkly Rep.* 2018; 67: 377-386.
- 5 Coleman AT, Jackson DJ, Gangnon RE et al. Comparison of risk factors for viral and nonviral asthma exacerbations. *J Allergy Clin Immunol.* 2015; 136:1127-9.e4.
- 6 Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. *J Allergy Clin Immunol Pract.* 2017; 5: 918-927.
- 7 Loymans RJB, Debray TPA, Honkoop PJ, et al. Exacerbations in adults with asthma: a systematic review and external validation of prediction models. *J Allergy Clin Immunol Pract* 2018; 6: 1942-1952.
- 8 Greenberg S. Asthma exacerbations: predisposing factors and prediction rules. *Curr Opin Allergy Clin Immunol.* 2013; 13: 225-236.
- 9 Miller MK, Lee JH, Miller DP, Group TS. Recent asthma exacerbations: a key predictor of future exacerbations. *Respir Med.* 2007; 101: 481-489.
- 10 Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med.* 2009; 180: 59-99.
- 11 Singh AM, Busse WW. Asthma exacerbations. 2: aetiology. *Thorax.* 2006; 61: 809-816.
- 12 Kelsen SE, Kelsen DP, Fleegler BF, et al. Emergency room assessment and treatment of patients with acute asthma. Adequacy of the conventional approach. *Am J Med.* 1978 64: 622-628.
- 13 Aldington S, Beasley R. Asthma exacerbations. 5: assessment and management of severe asthma in adults in hospital. *Thorax.* 2007; 62: 447-58.
- 14 Nowak RM, Tomlanovich MC, Sarkar DD, et al. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. *JAMA.* 1983; 249: 2043.
- 15 Carruthers D M, Harrison BDW. Arterial blood gas analysis or oxygen saturation in the assessment of acute asthma. *Thorax.* 1995; 50: 186-188.
- 16 Corre KA, Rothstein RR. Assessing severity of adult asthma and need for hospitalization. *Ann Emerg Med.* 1985; 14: 45-52.
- 17 Reddel HK, Barnes DJ. Pharmacological strategies for self-management of asthma exacerbations. Exacerbation Advisory Panel. *Eur Respir J.* 2006; 28: 182-199.
- 18 Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane Database Syst Rev.* 2013; 9: CD000052.
- 19 Newman KB, Milne S, Hamilton C, Hall K. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. *Chest.* 2002; 121: 1036-1041.
- 20 Perrin K, Wijesinghe M, Healy B, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. *Thorax.* 2011; 66: 937.

- 21 O'Driscoll BR, Howard LS, Earis J, Mak V; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. *Thorax.* 2017; 72: ii1-ii90.
- 22 Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. *Cochrane Database Syst Rev.* 2016; 5: CD011801.
- 23 Rowe BH, Spooner C, Ducharme FM, et al. Early emergency department treatment of acute asthma with systemic corticosteroids. *Cochrane Database Syst Rev.* 2001; 1: CD002178.
- 24 Sears MR. Adverse effects of beta-agonists. *J Allergy Clin Immunol.* 2002; 110: S322-S328.
- 25 Siegel D, Sheppard D, Gelb A, Weinberg PF. Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma. *Am Rev Respir Dis.* 1985; 132: 283-286.
- 26 Schatz M, Rachelefsky G, Krishnan JA. Follow-up after acute asthma episodes: what improves future outcomes? *Proc Am Thorac Soc.* 2009; 6: 386-393.
- 27 Toelle BG, Ram FS. Written individualised management plans for asthma in children and adults. *Cochrane Database Syst Rev.* 2004; 2: CD002171.
- 28 Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. *Thorax.* 2004; 59: 94-99.
- 29 Osborne J, Mortimer K, Hubbard RB, et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. *Am J Respir Crit Care Med.* 2009; 180: 598-602.
- 30 Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. *Respir Res.* 2011; 12: 38.
- 31 Powell H, Gibson PG. Options for self-management education for adults with asthma. *Cochrane Database Syst Rev.* 2003; 1: CD004107.